The FDA has approved a polypill as an initial treatment for hypertension in adults for the first time.
Here’s what to know:
1. Widaplik — manufactured by George Medicines — is a polypill that contains telmisartan, amlodipine and indapamide.
2. Historically, monotherapies have been the initial treatment for hypertension. This is the first triple-combination medication to be approved for patients who are likely to need multiple drugs to achieve their blood pressure goals, according to a June 9 company release.
3. In trials, the polypill reduced systolic blood pressure by around 7 to 8 mm Hg versus placebo in people with mild-to-moderate hypertension. It also showed small but significant blood pressure reductions compared to other dual drug combinations.
4. Widaplik is expected to be available in fourth-quarter 2025.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
